Genmab AS (LTS:0MGB) Other Operating Expense : kr0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2010. Start your Free Trial

What is Genmab AS Other Operating Expense?

Genmab AS's Other Operating Expense for the three months ended in Mar. 2025 was kr-0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 was kr0 Mil.

Genmab AS's quarterly Other Operating Expense declined from Sep. 2024 (kr0 Mil) to Dec. 2024 (kr0 Mil) and declined from Dec. 2024 (kr0 Mil) to Mar. 2025 (kr-0 Mil).

Genmab AS's annual Other Operating Expense declined from Dec. 2022 (kr-0 Mil) to Dec. 2023 (kr-0 Mil) but then increased from Dec. 2023 (kr-0 Mil) to Dec. 2024 (kr0 Mil).

Genmab AS Other Operating Expense Historical Data

The historical data trend for Genmab AS's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Other Operating Expense Chart

Genmab AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Operating Expense

Get a 7-Day Free Trial

-0.01

Genmab AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Operating Expense	Get a 7-Day Free Trial															-	-	0.01	-	-

Genmab AS Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0 Mil.

Genmab AS Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Genmab AS's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (LTS:0MGB) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

GNMSF:USA GMAB:USA GMAB:Mexico GMABc:UK GMAB:Denmark GE91:Germany GMAB:Austria

Address

Carl Jacobsens Vej 30, Valby, DNK, 2500

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines